Antiarrhythmic drugs, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.

The global Antiarrhythmic Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Antiarrhythmic Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antiarrhythmic Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Antiarrhythmic Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Antiarrhythmic Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly and Company
Sanofi SA
Bristol-Myers Squibb
Bayer
GlaxoSmithKline
Teva Pharmaceutical

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Oral Antiarrhythmic
Intravenous Antiarryhthmic

Segment by Application
Hospitals
Clinics